Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: A case series

International Journal of Clinical Oncology

Volumn 16, Issue 5, 2011, Pages 596-600

  Hayashi, Naoki ^a,b,c   Nakamura, Seigo ^b,c   Yagata, Hiroshi ^b   Shimoda, Yuji ^d   Ota, Hidekazu ^c   Hortobagyi, Gabriel N ^a   Cristofanilli, Massimo ^e   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SRL INC   (Japan)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast neoplasm; Circulating tumor cell; HER2; Metastasis; Polysomy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; LAPATINIB; PROGESTERONE RECEPTOR; SUNITINIB; TRASTUZUMAB; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER HORMONE THERAPY; CELL COUNT; CHROMOSOME 17; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE BREAST CANCER; POSITIVE BREAST CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; BREAST TUMOR; CASE REPORT; CHROMOSOME ABERRATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; POLYPLOIDY; TUMOR EMBOLISM;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; POLYPLOIDY; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84857065490     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0173-3     Document Type: Article

References (30)

1. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712 (Pubitemid 19147683)
2. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726 (Pubitemid 34111379)
3. Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948
4. Revillion F, Bonneterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808 (Pubitemid 28248487)
5. Esteva FJ, Valero V, Booser D et al (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808 (Pubitemid 34273269)
6. Seidman AD, Fornier MN, Esteva FJ et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595 (Pubitemid 32441364)
7. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
8. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36 (Pubitemid 46039831)
9. Pauletti G, Godolphin W, Press MF et al (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72 (Pubitemid 26248546)
10. Downey L, Livingston RB, Koehler M et al (2010) Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res 16:1281-1288
11. Vanden Bempt I, Van Loo P, Drijkoningen M et al (2008) Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869-4874
12. Dowsett M, Procter M, McCaskill-Stevens W et al (2009) Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 27:2962-2969
13. Hofmann M, Stoss O, Gaiser T et al (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 61:89-94 (Pubitemid 351158232)
14. Watters AD, Going JJ, Cooke TG et al (2003) Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 77:109-114 (Pubitemid 36197611)
15. Hyun CL, Lee HE, Kim KS et al (2008) The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol 61:317-321 (Pubitemid 351354237)
16. Downs-Kelly E, Yoder BJ, Stoler M et al (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221-1227 (Pubitemid 41232996)
17. Reinholz MM, Bruzek AK, Visscher DW et al (2009) Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 10:267-277
18. Merola R, Mottolese M, Orlandi G et al (2006) Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42:1501-1506 (Pubitemid 43903166)
19. Cristofanilli M, Broglio KR, Guarneri V et al (2007) Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 7:471-479 (Pubitemid 46424284)
20. Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791 (Pubitemid 39095313)
21. Cristofanilli M, Hayes DF, Budd GT et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-1430
22. Hayes DF, Cristofanilli M, Budd GT et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218-4224
23. Nakamura S, Yagata H, Ohno S et al (2009) Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17:199-204
24. Yagata H, Nakamura S, Toi M et al (2008) Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. Int J Clin Oncol 13:252-256 (Pubitemid 351871893)
25. Fehm T, Becker S, Duerr-Stoerzer S et al (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9:R74
26. Reuben JM, Lee BN, Li C et al (2007) Genomic of circulating tumor cells in metastatic breast cancer. J Clin Oncol 25:1002
27. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
28. Shimada M, Imura J, Kozaki T et al (2005) Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Oncol Rep 13:633
29. Meng S, Tripathy D, Shete S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101:9393-9398 (Pubitemid 38812885)
30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)